Stocks and Investing
Stocks and Investing
Thu, November 16, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, November 15, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Leland Gershell Maintained (URGN) at Buy with Decreased Target to $32 on, Nov 15th, 2023
Leland Gershell of Oppenheimer, Maintained "UroGen Pharma Ltd." (URGN) at Buy with Decreased Target from $33 to $32 on, Nov 15th, 2023.
Leland has made no other calls on URGN in the last 4 months.
There are 2 other peers that have a rating on URGN. Out of the 2 peers that are also analyzing URGN, 1 agrees with Leland's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Paul Choi of "Goldman Sachs" Maintained at Hold with Increased Target to $18 on, Monday, July 31st, 2023
This is the rating of the analyst that currently disagrees with Leland
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $54 on, Wednesday, October 4th, 2023
Contributing Sources